Stem Cell Differentiation via PKC Activator
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for differentiating human embryonic stem cells into insulin-producing cells are inefficient and do not closely resemble β cells, which are necessary for effective cell-replacement therapy in Type I diabetes mellitus.
Innovation Solution
A method involving the differentiation of pluripotent stem cells into a population expressing markers characteristic of the pancreatic endoderm lineage by culturing them in a medium supplemented with a protein kinase C activator, resulting in greater than 50% of the cells co-expressing PDX1 and NKX6.1, which are critical markers for pancreatic endoderm cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional differentiation methods are used, then cell differentiation occurs, but the efficiency is low and β cell resemblance is poor
Solution Approach 1:
The patent changes the chemical parameters of the culture medium by adding specific agents (activin A, FGF7, retinoic acid, DKK1) at controlled concentrations and time points. This systematically modifies the differentiation conditions to guide stem cells toward pancreatic endoderm lineage with higher efficiency and better β cell characteristics
Solution Approach 2:
The patent applies preliminary actions by first inducing definitive endoderm formation before transitioning to pancreatic endoderm. This staged approach with pre-defined intermediate states ensures proper lineage commitment and improves final differentiation outcomes
2Productivity
If differentiation is accelerated, then productivity increases, but cell quality and functional resemblance to β cells may decrease
Solution Approach 1:
The patent segments the differentiation process into distinct stages: definitive endoderm formation, pancreatic endoderm transition, and β cell lineage specification. Each stage has specific duration and chemical conditions, allowing controlled acceleration without compromising functional quality
Solution Approach 2:
The patent employs periodic action through time-dependent addition of differentiation agents. Specific chemicals are added at defined time intervals (e.g., activin A for 4 days, then FGF7 and retinoic acid subsequently), creating a rhythmic differentiation protocol that maintains cell quality while improving productivity
Data Source
Figure 1A~1B
Figure 2A~2B
Figure 3A~3C
AI summary
The present invention provides methods to promote the differentiation of pluripotent stem cells into insulin producing cells. In particular, the present invention provides a method to produce a population of cells expressing markers characteristic of the pancreatic endoderm lineage, wherein greater than 50% of the cells in the population co-express PDX1 and NKX6.1.